BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Leukocyte
,
Holistic medicine
,
Rosiglitazone
,
rs2230926
,
PBX1
,
Angiogenesis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Complement C5
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Liver
Fetal liver
Duodenum
Stomach fundus
Pancreas
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Severe acute respiratory syndrome
Viral disease
Acute hepatic failure
Hepatic failure
Complement deficiency disease
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Acetylcysteine
eculizumab
Nickel
imiglucerase
Gonanes
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
MLXIPL
APPL1
PTPN6
HSD17B10
NOP2
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Prostate cancer metastatic tumors with PTEN RB1 TRP53 triple knockout
Expression in hepatic cells expressing or not expressing Foxl1
Liver gene expression response to circadian rhythm disruption
Lung tumors from KRAS G12D expressing mice treated with N-acetylcysteine (NAC) or vitamin E
Lung epithelial EPCAM+ cells from E18.5 embryos with MST1 and MST2 conditional double knockout
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for Complement C5
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibito…
Complement Activation in the Lysosomal Storage Disorders
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participa…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ